Taking the above into consideration, and that WHSC1L1 has overall low expression levels in normal tissues28, this protein lysine methyltransferase may represent an important target for drug development in SCCHN patients with aberrant expression of this enzyme. This evidence concerns the gene NSD3 and head and neck squamous cell carcinoma.